Arrowstreet Capital Limited Partnership boosted its position in shares of ChemoCentryx (NASDAQ:CCXI) by 44.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,016 shares of the biopharmaceutical company’s stock after acquiring an additional 8,017 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.05% of ChemoCentryx worth $155,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wells Fargo & Company MN increased its holdings in shares of ChemoCentryx by 41.0% in the fourth quarter. Wells Fargo & Company MN now owns 48,636 shares of the biopharmaceutical company’s stock valued at $290,000 after purchasing an additional 14,133 shares during the last quarter. Iguana Healthcare Management LLC increased its holdings in shares of ChemoCentryx by 10.0% in the third quarter. Iguana Healthcare Management LLC now owns 275,000 shares of the biopharmaceutical company’s stock valued at $2,041,000 after purchasing an additional 25,000 shares during the last quarter. OxFORD Asset Management LLP increased its holdings in shares of ChemoCentryx by 37.3% in the third quarter. OxFORD Asset Management LLP now owns 246,369 shares of the biopharmaceutical company’s stock valued at $1,853,000 after purchasing an additional 66,910 shares during the last quarter. ING Groep NV acquired a new position in shares of ChemoCentryx in the third quarter valued at $223,000. Finally, ClariVest Asset Management LLC increased its holdings in shares of ChemoCentryx by 20.2% in the third quarter. ClariVest Asset Management LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $371,000 after purchasing an additional 8,400 shares during the last quarter. 48.39% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CCXI stock traded down $0.33 on Friday, hitting $12.33. The company’s stock had a trading volume of 150,879 shares, compared to its average volume of 388,506. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.46 and a current ratio of 5.46. ChemoCentryx has a fifty-two week low of $5.42 and a fifty-two week high of $15.08. The company has a market capitalization of $603.20, a PE ratio of 34.25 and a beta of 1.58.
ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings results on Friday, March 9th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $1.02. The business had revenue of $56.30 million during the quarter, compared to analyst estimates of $9.03 million. analysts forecast that ChemoCentryx will post -1.18 EPS for the current year.
Several equities analysts have commented on CCXI shares. BidaskClub upgraded shares of ChemoCentryx from a “strong sell” rating to a “sell” rating in a report on Saturday, March 3rd. JPMorgan Chase reiterated an “overweight” rating and issued a $16.00 price objective (up from $13.00) on shares of ChemoCentryx in a report on Tuesday, March 13th. Zacks Investment Research upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Wednesday, March 14th. Finally, ValuEngine upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating in a research note on Wednesday, March 14th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $15.00.
TRADEMARK VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/arrowstreet-capital-limited-partnership-has-155000-holdings-in-chemocentryx-inc-ccxi.html.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.